Career Opportunity

Field Medical Affairs Director Italy*

Life Molecular Imaging GmbH (LMI) is a German-based Research & Development (R&D) organization focused on developing PET imaging and radiotheranostics solutions for diseases with high unmet medical needs. Our vision is to build our position as an innovator and leading player in the Nuclear Medicine field. We aim to create value for patients & physicians by improving early detection and characterization of chronic and life-threatening diseases leading to better therapeutic outcomes and improved quality of life.

We offer the following full-time position located in Italy:

Field Medical Affairs Director Italy*

The Medical Affairs Director for Italy will provide medical leadership in the field of neuroimaging, with a particular focus on dementias and cognitive decline. The role requires a senior Medical Affairs professional with scientific and/or medical expertise, preferably in neurodegenerative diseases and neuroimaging. The candidate should reside in Italy and have 5-10 years of experience in Medical Affairs within the pharmaceutical or biotech industry.

Main Tasks & Responsibilities:

  • Execution of the medical affairs strategy for Italy.
  • Support launch strategies, life-cycle management, and expansion of indications for use.
  • Liaise closely with other Medical Affairs Directors in the Europe, US, and RoW to design coordinated global / regional brand strategies.
  • KOL mapping of the territories.
  • Liaise with health authorities regarding drug access programs.
  • Support company-sponsored clinical research and medical publications.
  • Identify, develop, and maintain peer-to-peer relationships with Medical Experts/Key Stakeholders.
  • Attend relevant scientific meetings and conferences.
    Responsible for medical aspects of HTA dossiers.
    Provide medical and scientific support for product messaging, claims development, and marketing activities.
  • Ensure compliance with applicable local and global laws, regulations, guidelines, and company policies and procedures.

Skills:

  • Excellent communication skills and managerial skills, as well as the ability to work collaboratively
  • Fluent in English and Italian
  • Ability to travel as required
  • Excellent organizational and time management skills
  • MS Office skills, especially Word, Excel, and PowerPoint

 Experience/ Education:

  • Medical Doctor / PhD / PharmD / or equivalent.
  • 5-10 years in Medical Affairs in pharmaceutical / biotech industry, preferably in neurodegenerative diseases and/or neuroimaging.
  • In-depth knowledge in Neurology and/or PET imaging.
  • Strong understanding of pharmaceutical development, clinical trials, and regulatory processes.

If you want to become part of an entrepreneurial team, if you are prepared to assume a wide range of responsibilities, and if your background and personal experience fit this profile, we invite you to apply. Don’t forget to include a cover letter detailing your interest in this position and your past relevant work experience and a CV.

Please submit your application on our website: https://life-mi.com/careers/

Dr. Andrew Stephens / Dr. Christiane Pering
Life Molecular Imaging

We are currently accepting applications and look forward to receiving yours.

*The person counts, not the gender! Life Molecular Imaging is committed to diversity, rejects discrimination, and does not think in categories such as gender, ethnic origin, religion, disability, age, or sexual identity. Life Molecular Imaging GmbH is an Equal Opportunity Employer. We believe what we do and our culture of “More Than a Job. It’s Making Life Better” extends to creating a welcoming, safe, and inclusive work environment.

Apply here
Neuraceq® - Product Indications And Use

PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.

Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS

  • Risk for Image Misinterpretation and other Errors
    Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation [see Clinical Studies (14)]. Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.
  • Radiation Risk
    Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration.

ADVERSE REACTIONS:

  • The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/appliucation site erythema (1.7%), injection site irritation (1.1%).

DRUG INTERACTIONS

  • Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: All radiopharmaceuticals, including Neuraceq, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Neuraceq administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
  • Lactation: There are no data on the presence of florbetaben F 18 injection in human milk, the effects on the breastfed infant, or the effects of florbetaben F 18 injection on milk production. Exposure of Neuraceq to a breastfed infant can be minimized by temporary discontinuation of breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Neuraceq and any potential adverse effects on the breastfed child from Neuraceq or from the underlying maternal condition.
  • Pediatric Use: Neuraceq is not indicated for use in pediatric patients.
  • Geriatric Use: No overall differences in safety were observed between older and younger subjects

OVERDOSAGE
A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.

SUSPECTED ADVERSE REACTIONS please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

.
.
.
.
.